window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 14, 2025

  • News
  • About Us
Contact Us

chronic liver disease

  • Artificial Intelligence,Biologics & Biosimilars,Biotech,Cell & Gene Therapy,Chronic diseases,Drug Development,Genomics and sequencing,Precision medicine,Research & Development

    Mursla Bio partners with global pharma to advance biomarker-guided precision medicine in MASH

    Mursla Bio has announced a collaboration with a leading global [...]

    November 13, 2025
  • Drug Development,Global health,Patient Centricity,Research & Development

    Vitamin D shown to reduce liver damage by activating TXNIP gene, study finds

    New study shows how the vitamin D/TXNIP axis modulates ductular [...]

    July 28, 2025
  • Artificial Intelligence,Drug Development

    Ochre Bio founder takes helm as CEO to drive RNA liver therapies towards clinic

    RNA therapeutics biotech Ochre Bio has appointed its founder and [...]

    July 7, 2025
  • Cell & Gene Therapy

    Hydrogel breakthrough could boost liver cell therapy durability, Likarda paper shows

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top